相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Yingming Li et al.
CLINICAL CANCER RESEARCH (2020)
Treatment of Advanced Prostate Cancer
Min Yuen Teo et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Hypoxia Patterns in Primary and Metastatic Prostate Cancer Environments
Santosh Kumar Bharti et al.
NEOPLASIA (2019)
A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naive metastatic castration-resistant prostate cancer.
Enrique Grande et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
Louie Semaan et al.
BMC CANCER (2019)
Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene
Jindan Luo et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer
W. Han et al.
ONCOGENE (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Qiuhui Li et al.
NATURE COMMUNICATIONS (2018)
CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α
Xi Tian et al.
CANCER RESEARCH (2017)
Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting
Parvez M. Lokhandwala et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Mechanisms of Therapeutic Resistance in Prostate Cancer
Mary Nakazawa et al.
CURRENT ONCOLOGY REPORTS (2017)
TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences
Cindy Ke Zhou et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2017)
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
Elizabeth Pham et al.
CANCER RESEARCH (2016)
In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated beta-Cyclodextrin Nanosponges in Prostate Cancer
Casimiro Luca Gigliotti et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2016)
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
Irfan A. Asangani et al.
MOLECULAR CANCER RESEARCH (2016)
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
Andrew J. Clark et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis
Chien-Ju Lin et al.
ONCOTARGET (2016)
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
Steven Kregel et al.
ONCOTARGET (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
Blockade of ARV7:HIF1a heterodimers after topotecan reverses enzalutamide resistance in 22Rv1 cells.
John P. Fruehauf et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Luana Schito et al.
TRENDS IN CANCER (2016)
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
Sarah J. Conley et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
Chengfei Liu et al.
CANCER RESEARCH (2015)
Ligand-Dependent Enhancer Activation Regulated by Topoisomerase-I Activity
Janusz Puc et al.
CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings
Avelino Fraga et al.
CLINICAL GENITOURINARY CANCER (2015)
Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels
Alba Font-Tello et al.
PROSTATE (2015)
Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Elizabeth Pham et al.
CLINICAL CANCER RESEARCH (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Dual Targeting of the Androgen Receptor and Hypoxia-Inducible Factor 1α Pathways Synergistically Inhibits Castration-Resistant Prostate Cancer Cells
Elena V. Fernandez et al.
MOLECULAR PHARMACOLOGY (2015)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer
Shikha Gaur et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanisms of the androgen receptor splicing in prostate cancer cells
L. L. Liu et al.
ONCOGENE (2014)
Topoisomerase Inhibitors Modulate Gene Expression of B-Cell Translocation Gene 2 and Prostate Specific Antigen in Prostate Carcinoma Cells
Kun-Chun Chiang et al.
PLOS ONE (2014)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
Hypoxia enhances ligand-occupied androgen receptor activity
Choa Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
The updated biology of hypoxia-inducible factor
Samantha N. Greer et al.
EMBO JOURNAL (2012)
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells
Rosalba Minelli et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Coordinated Action of Hypoxia-inducible Factor-1α and β-Catenin in Androgen Receptor Signaling
Takakazu Mitani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
Changmeng Cai et al.
CANCER CELL (2011)
Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
Yingming Li et al.
CANCER RESEARCH (2011)
Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth
Shicheng Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
The relevance of a hypoxic tumour microenvironment in prostate cancer
Grant D. Stewart et al.
BJU INTERNATIONAL (2010)
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
G. L. Semenza
ONCOGENE (2010)
Reactivation of Androgen Receptor-Regulated TMPRSS2:ERG Gfene Expression in Castration-Resistant Prostate Cancer
Changmeng Cai et al.
CANCER RESEARCH (2009)
Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment
Sofia Halin et al.
PROSTATE (2007)
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line:: A new perspective for an old model
Kirsten D. Mertz et al.
NEOPLASIA (2007)
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models
T Schluep et al.
CLINICAL CANCER RESEARCH (2006)
Topotecan blocks hypoxia-inducible factor-1α, and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells
Y Beppu et al.
CANCER RESEARCH (2005)
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
A Rapisarda et al.
CANCER RESEARCH (2004)
Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
A Rapisarda et al.
CANCER RESEARCH (2004)
分享论文
